Feds Probe Marketing of 3 Merck & Co., Inc. Drugs
Published: Aug 08, 2011
Merck & Co., the second-largest U.S. drugmaker, received a subpoena from the Department of Justice related to the sales of three cancer and viral drugs. The U.S. department asked for details of the marketing and selling of Temodar, PegIntron and Intron A, from January 1, 2004 to the present “in a federal health-care investigation,” Merck said today in a filing. “This is the first disclosure of this matter,” Ronald Rogers, a spokesman for Whitehouse Station, New Jersey-based Merck, said in an e-mail. The drugmaker is cooperating with the investigation, Rogers said, declining to provide additional information.